DS-1205c
Phase 2Small molecule
Daiichi SankyoDS-1205c is one of 70 small molecule programs targeting Necrosis. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1PORTRAZZA
Eli LillyPreclinical
Imjudo
AstraZenecaPreclinical
Vizimpro
PfizerPreclinical
DS-1205c
Daiichi SankyoPhase 2
Tyrosine Kinase Inhibitor
PfizerPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
REGN2810
RegeneronPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Treatment
GSKPreclinical
Vidaza
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DS-1205c. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company